Isofluran Baxter (Isoflurane)

Isoflurane works by enhancing the activity of GABA_A receptors, which increases inhibitory neurotransmission, and by blocking NMDA receptors, reducing excitatory signaling. This combined effect depresses neuronal activity, leading to unconsciousness and analgesia required for anesthesia.

The specific dose and concentration of Isofluran Baxter are determined by the treating anesthesiologist based on the patient’s age, weight, health status, and the type of procedure. The prescriber sets the appropriate vaporizer settings and administration parameters.

The safety of isoflurane during pregnancy and lactation has not been established. It is generally avoided in pregnant patients unless the benefits outweigh the potential risks, and breastfeeding mothers should consult their healthcare provider before exposure.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Isoflurane offers a relatively low blood‑gas partition coefficient, providing faster induction and recovery compared with agents like halothane, while maintaining stable cardiovascular profiles. It is often chosen for its predictable depth of anesthesia and lower incidence of hepatic toxicity relative to older volatile agents.

Isofluran Baxter should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the product from direct sunlight, moisture, and physical damage. Ensure the vaporizer and delivery system are cleaned according to manufacturer guidelines before use.

Isofluran Baxter is administered via inhalation using a calibrated vaporizer attached to a breathing circuit. The anesthesiologist adjusts the vaporizer setting to achieve the desired minimum alveolar concentration (MAC) while continuously monitoring the patient’s vital signs.

The most serious risks include malignant hyperthermia, a rare but life‑threatening hypermetabolic reaction, severe hypotension, and respiratory depression. Prompt recognition and treatment are essential, and patients with known susceptibility to malignant hyperthermia should not receive isoflurane.

Isofluran Baxter should be avoided in patients with a known susceptibility to malignant hyperthermia, severe hepatic impairment, or uncontrolled cardiovascular instability. It is also contraindicated in pregnant women unless absolutely necessary and should be used with caution in patients taking other central nervous system depressants.